Comments

TransCode Therapeutics

Q: What sector and industry does TransCode Therapeutics (RNAZ) operate in?

TransCode Therapeutics is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.

RNAZNASDAQ

Logo brought to you by Benzinga Data

Perks Buy Compare Brokers

TransCode Therapeutics (RNAZ) Forecast

News Earnings TransCode Therapeutics (RNAZ) Options Guidance Dividends Analyst Ratings Insider Trades Short Interest

Edge Rankings

Want to View Edge Rankings?

Unlock The Hidden Results With Your Benzinga Account Now.

Get Started

TransCode Therapeutics (NASDAQ:RNAZ) Stock Quotes, Forecast and News Summary

TransCode Therapeutics Stock (NASDAQ: RNAZ) stock price, news, charts, stock research, profile.

Open	$9.22
Close	-
Volume / Avg.	18.34K / 1.66M
Day Range	$9.00 - $9.49
52 Wk Range	2.66 - 66.33
Market Cap	$6.28M
P/E Ratio	0.00
Dividend Yield	-
Exchange	NASDAQ
RSI	50
Short Interest	52.9%
Days to Cover	1

Recent News

TransCode Therapeutics Shares Are Surging Today: What's Going On?

TransCode Therapeutics Inc. (NASDAQ: RNAZ) shares are moving higher Friday after the company announced that the first patient in Cohort 3 of its Phase 1 clinical trial has been dosed with its lead candidate, TTX-MC138 on Tuesday.

Vaishali Prayag

Crude Oil Gains Over 1%, General Mills Shares Fall

Avi Kapoor

Dow Surges 150 Points, US Current Account Deficit Widens In Q3

Avi Kapoor

Financials

Quarterly

Annual

Name

Revenue Change
Gross Change
EBITDA Change
EBIT Change
Earnings Change

Analyst Trends and Forecast

Sep 24

Oct 24

Nov 24

Dec 24

Feb

Buy

Hold

Sell

Strong Sell

Analyst Rating and Forecast

4.0

Buy

Strong Buy

Buy

Hold

Sell

Strong Sell

Open	$9.22
Close	-
Volume / Avg.	18.34K / 1.66M
Day Range	$9.00 - $9.49
52 Wk Range	2.66 - 66.33
Market Cap	$6.28M
P/E Ratio	0.00
Dividend Yield	-
Exchange	NASDAQ
RSI	50
Short Interest	52.9%
Days to Cover	1

About TransCode Therapeutics Inc

Sector

Health Care

Industry

Biotechnology

TransCode Therapeutics Inc is a clinical-stage oncology company focused on treating metastatic disea...

Compare

EPS worse than industry

Earnings Per Share

EPS is the portion of a company's profit allocated to each outstanding share of common stock. It is a key metric for investors to assess a company's profitability.

Earnings Per Share

EPS is the portion of a company's profit allocated to each outstanding share of common stock. It is a key metric for investors to assess a company's profitability.

EPS worse than industry

FAQ

How do I buy TransCode Therapeutics (RNAZ) stock?

You can purchase shares of TransCode Therapeutics (NASDAQ:RNAZ) through any online brokerage.

View our list of the best stock brokerages

Who are TransCode Therapeutics (RNAZ) competitors?

Other companies in TransCode Therapeutics’s space includes: CERo Therapeutics Hldgs (NASDAQ:CERO), Galecto (NASDAQ:GLTO), Alzamend Neuro (NASDAQ:ALZN), Dermata Therapeutics (NASDAQ:DRMA) and Portage Biotech (NASDAQ:PRTG).

What is the forecast, or price target, for TransCode Therapeutics (RNAZ) stock?

TransCode Therapeutics has a consensus price target of $20.00.

What is the current price for TransCode Therapeutics (RNAZ)?

The stock price for TransCode Therapeutics (NASDAQ: RNAZ) is $9.0197 last updated February 21, 2025 at 10:25 AM EST.

Does TransCode Therapeutics (RNAZ) pay a dividend?

There are no upcoming dividends for TransCode Therapeutics.

When is TransCode Therapeutics (NASDAQ:RNAZ) reporting earnings?

TransCode Therapeutics’s Q1 earnings are confirmed for Wednesday, May 14, 2025.

Is TransCode Therapeutics (RNAZ) going to split?

There is no upcoming split for TransCode Therapeutics.

What sector and industry does TransCode Therapeutics (RNAZ) operate in?

TransCode Therapeutics is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.